Next Article in Journal
Hypoglicemic and Hypolipedimic Effects of Ganoderma lucidum in Streptozotocin-Induced Diabetic Rats
Next Article in Special Issue
The Expanding Role of Radiosurgery for Brain Metastases
Previous Article in Journal
Bioactive Compounds and Extracts from Traditional Herbs and Their Potential Anti-Inflammatory Health Effects
Previous Article in Special Issue
Assessing Novel Drugs and Radiation Technology in the Chemoradiation of Oropharyngeal Cancer
Article Menu
Issue 3 (September) cover image

Export Article

Open AccessReview
Medicines 2018, 5(3), 77; https://doi.org/10.3390/medicines5030077

Evolution of Stereotactic Ablative Radiotherapy in Lung Cancer and Birmingham’s (UK) Experience

Hall-Edwards Radiotherapy Research Group, Queen Elizabeth Hospital, Birmingham B15 2TH, UK
*
Author to whom correspondence should be addressed.
Received: 26 June 2018 / Revised: 20 July 2018 / Accepted: 21 July 2018 / Published: 23 July 2018
(This article belongs to the Special Issue Advances and Perspectives in Radiotherapy Treatments)
Full-Text   |   PDF [268 KB, uploaded 23 July 2018]

Abstract

Stereotactic ablative radiotherapy (SABR) has taken a pivotal role in early lung cancer management particularly in the medically inoperable patients. Retrospective studies have shown this to be well tolerated with comparable results to surgery and no significant increase in toxicity. Paucity of randomized evidence has dictated initiation of several trials to provide good quality evidence to steer future practice. This review summaries salient developments in lung SABR, comparisons to surgery and other platforms and our local experience at University Hospitals Birmingham, UK of lung SABR since its initiation in June 2013. View Full-Text
Keywords: lung cancer; radiotherapy; stereotactic ablative radiotherapy (SABR); stereotactic body radiotherapy (SBRT); radiofrequency ablation (RFA); microwave ablation; dosimetry; radiotherapy treatment techniques lung cancer; radiotherapy; stereotactic ablative radiotherapy (SABR); stereotactic body radiotherapy (SBRT); radiofrequency ablation (RFA); microwave ablation; dosimetry; radiotherapy treatment techniques
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Yahya, S.; Ghafoor, Q.; Stevenson, R.; Watkins, S.; Allos, B. Evolution of Stereotactic Ablative Radiotherapy in Lung Cancer and Birmingham’s (UK) Experience. Medicines 2018, 5, 77.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Medicines EISSN 2305-6320 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top